Premium
α‐Adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect
Author(s) -
Naslund T C,
Merrell W J,
Nadeau J H,
Wood A J J
Publication year - 1988
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1988.214
Subject(s) - ketanserin , prazosin , phenylephrine , medicine , pharmacology , antagonist , blockade , blood pressure , adrenergic , endocrinology , anesthesia , serotonin , receptor , 5 ht receptor
Ketanserin is a selective (S 2 ) serotonin receptor antagonist currently under investigation as an antihypertensive. It has been suggested that the antihypertensive action of ketanserin might be principally due to α‐adrenergic receptor antagonism rather than its effect on serotonin receptors. We therefore determined the contribution of α‐adrenergic blockade to the hypotensive effects of ketanserin in six patients with hypertension and compared that with the α‐adrenergic blockade produced by prazosin, a known α 1 ‐adrenergic antagonist. Each patient received placebo, ketanserin (40 mg every 8 hours), and prazosin (5 mg every 8 hours). Each agent was administered for 4 weeks in random order. Both ketanserin and prazosin lowered blood pressure significantly and to a similar extent. The extent of α‐adrenergic blockade was determined from the ability to inhibit the hypertensive effect of phenylephrine infusions. The dose of phenylephrine required to raise the blood pressure by 20 mm Hg was significantly higher during both ketanserin (1.41 ± 0.27 μg/kg/min; p < 0.05) and prazosin (4.99 ± 0.77 μg/kg/min; p 0.01) administration compared with placebo (0.85 ± 0.15 μg/kg/min). However, the dose ratio was more than fourfold higher during prazosin treatment (7.38 ± 1.99; p < 0.05) than during ketanserin (1.69 ± 0.21). Thus at equipotent hypotensive doses the extent of α‐blockade produced by ketanserin was more than fourfold lower than that of prazosin, implying that mechanisms other than α‐blockade must contribute to the antihypertensive actions of ketanserin. Clinical Pharmacology and Therapeutics (1988) 44 , 699–703; doi: 10.1038/clpt.1988.214